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Chronic liver disease occurs throughout the world irrespective of age, sex, region or
race. Cirrhosis is an end result of a variety of liver diseases characterized by fibrosis and
architectural distortion of the liver with the formation of regenerative nodules and can have
varied clinical manifestation and complications. According to WHO, about 46 % of global
diseases and 59 % of the mortality is because of chronic diseases and almost 35 million
people in the world die of chronic diseases.1 Liver diseases rates are steadily increasing over
the years. According to national statistic in the UK, liver diseases have been ranked as fifth
most common cause of death.2 Liver diseases are recognized as the second leading cause of
mortality amongst all digestive diseases in US.3
SILYMARIN:
Silybum marianum, commonly known as milk thistle in the family Asteraceae, is one
of the oldest and thoroughly researched plants of ancient times for the treatment of liver and
gallbladder disorders, hepatitis, cirrhosis, jaundice and protection against Amanita phalloides
mushroom and other toxin poisonings4. Silymarin, the active component of this plant, is a
standardized extract consisting of approximately 70 to 80 percent silymarin flavanoliganans
(silybin A & B, isosilybin A & B, silydianin and silychristin) and flavanoids (toxifolin and
quercetin), and the remaining 20 to 30 percent consisting of a chemically undefined fraction
comprised of polymeric and oxidized polyphenolic compounds (Figure.1).5
Silymarin possess wide range of biological and pharmacological effects, including
antioxidant activity,6 stimulation of protein synthesis and cell regeneration (making it useful
in the treatment of toxic liver damage, chronic inflammatory liver diseases and liver
cirrhosis),7,8 and impressive anticancer activity against several human carcinoma cell lines.9,10
In addition, anti-diabetic activity,11 cardioprotection,12 anti-inflammatory, anti-fibrotic,
hypolipidemic, neurotrophic and immune modulation effects.13
The water solubility of the drug is very poor14 (0.04 mg/ml). Oral administration of
silymarin (silybin) is rapidly absorbed with a tm ax 2 to 4 hours and its t1/2 is 6 hours. Only 20
– 50 percent of oral silymarin is absorbed from the gastrointestinal tract. Therefore,
absorption of silymarin from the gastrointestinal tract is low that leads poor bioavailability.15
Figure.1: Components of silymarin.
Developing novel strategies to enhance the solubility of poor water soluble drugs is
one of the mean focuses of pharmaceutical technology5, 6. The bioavailability of poorly
soluble drugs can be improved by conversion of micro particles to drug nanoparticles.
Nanotechnology mainly refers to the study of materials and structures at the nanosized level.
In micronization process of drugs the chance for agglomeration is high, so in order to avoid
the agglomeration, nano- scale systems are used. A nano- crystal is a material with
dimensions measured in nanometers, and particle size ranging from 1- 1000 nanometers.
Nanotechnology is a promising strategy for improving the dissolution rate and oral
bioavailability of poorly water soluble drugs by reducing the particle size and/or transforming
drug from a crystalline to an amorphous state7, 8.
RATIONALE OF DRUG TARGETING 16
The site-specific targeted drug delivery negotiates an exclusive delivery to specific
pre-identified compartments with maximum activity of drugs and concomitantly reduced
access of drug to irrelevant non-target cells. The controlled rate & mode of drug delivery to
pharmacological receptor and specific binding with target cells as well as bioenvironmental
protection of the drug in route to the site of action are specific features of targeting.
Invariably, every event stated contributes to higher drug concentration at the site of action
and resultant lowers concentration at non-target tissue where toxicity might crop up. The high
drug concentration at the target site is relative cellular result of the uptake of the drug vehicle,
liberation and efflux of free drug from the target site.
Targeting is signified if the target compartment is distinguished from the other
compartments, where toxicity may occur and also if the active drug could be placed
predominantly in the proximity of target site. The restricted distribution of the parent drug to
the non-target site(s) with effective accessibility to the target site(s) could maximize the
benefits of targeted drug delivery.
CARRIERS USED IN TARGETING DRUG DELIVERY SYSTEMS
Carrier is one of the most important entities essentially required for successful
transportation of the loaded drug(s). They are drug vectors, which sequester, transport and
retain drug en route. While eluting or delivering it within or in vicinity of target.
Colloidal carriers:
 Vesicular systems: liposomes; pharmacosomes; virosomes; immunoliposomes.
 Micro particulate systems: nanoparticles; microparticles; magnetic microspheres;
nanocapsules.
 Cellular carriers: resealed erythrocytes; serum albumin; antibodies; platelets;
leukocytes.
Supramolecular delivery system:
 Micelles; reverse micelles; mixed micelles; polymeric micelles; liquid crystal:
lipoproteins.
Polymer based systems:
 Signal sensitive; muco-adhesive; biodegradable; bioerodible; solute synthetic
polymeric carriers.
Macromolecular carriers:
 Proteins, glycoproteins, neo glycoproteins and artificial viral envelops (AVE);
Glycosylated water-soluble polymers (poly-L-lysine).
 Mabs; Immunological Fab fragments; antibody enzyme complex & bispesific Abs;
Toxins, immunotoxin & rCD4 toxin conjugates, Lecithins (Con A) &
polysaccharides.
INTRODUCTION TO LIPOSOMES 17
Liposomes have reached the clinical only recently, but they are not a new invention
Alec D. Bangham of the Agricultural Research Council’s institute of Animal physiology in
Cambridge, England, inadvertently produced the first liposome in 1961, while evaluating the
effect of phospholipids on blood clotting. When bangham put water in a flask containing a
phospholipid film, the water molecules to arrange themselves in to what he discovered. He
found vesicles composed of a bilayered phospholipids membrane surrounding water
entrapped from the environment.
Phospholipids form closed, fluid-filled spheres when they are mixed with water in
part because the molecules are amphipathic; they have a hydrophobic “tail” and a hydrophilic
or polar “head”. Two fatty acid chains, each composed of 10 to 24 carbon atoms, make up the
hydrophobic tail of most naturally occurring phospholipids molecules. Phosphoric acid bound
to any of several water soluble molecules composes the hydrophilic head. When a high
enough concentration of phospholipids is mixed with water, the hydrophobic tails
spontaneously herd together to exclude water, whereas the hydrophilic heads bind to water.
The result is a bilayer in which the fatty acid tails in to the membrane’s interior and
the polar head groups point outward the polar groups at one surface of the membrane point
toward the liposome’s interior and those at the other surface point toward the external
environment. It is this remarkable reactivity of phospholipids to water that enables workers to
load medications in to liposomes. In a liposome form, any water soluble molecules that have
been added to the water are incorporated in to the aqueous spaces in the interior of the
spheres, whereas any lipid soluble molecules added to the solvent during vesicle formation
are incorporated in to the lipid layer.
Liposomes employed for drug delivery typically range in diameter from 250 angstrom
units to several micrometers and are usually suspended in a solution. They have two standard
forms: “onion-skinned” multilamellar vesicles (MLVs) made up of several lipid bilayers
separated by fluid, and unilamellar vesicles, containing of a single bilayer surrounding an
entirely fluid core. The unilamellar vesicles are typically characterized as being small (SUVs)
or large (LUVs).
ADVANTAGES OF LIPOSOMES
The pharmaceutical and pharmacological justification of the use of liposomes as drug
carriers is as follows:
 Liposomal supply both a lipophilic environment and aqueous “milleu interne” in one
system and are therefore suitable for the delivery of hydrophobic, amphipatic and
hydrophilic drugs and agents.
 Liposomes are chemically and physically well characterized entities.
 The biological fate of liposomes after their administration is related to their
composition and physical properties.
 Liposomes are biocompatible due to their biodegradability, low toxicity and lack of
immunogenicity.
 Liposomes can serve as device for controlled release of drugs in body fluids (micro
reservoir concept) and inside cells (after endocytic uptake).
 Liposomes help to reduce exposure of sensitive tissues to toxic drugs.
 Liposomes can be administered through mostnroutes of administration including
ocular, pulmonary, nasal, oral, intramuscular, subcutaneous, topical and intravenous.
 Pharmacokinetics and in-vivo distribution of liposomes can be controlled by their port
of entry combined with their lipid composition and size.
DISADVANTAGES OF LIPOSOMES
 Aggregation, fusion and drug leakage during storage.
 Chemically instable i.e., degradable by oxidation and hydrolysis.
 In physiological environment they are destabilized by high density lipoproteins(HDL)
 Purity of natural phospholipids and cost of production.
 They undergo complete mediated phagocytosis and lipid exchange reactions.
For liposomes to enter the market, they must be stable during the storage period, and
remain intact before reaching their targeted tissues to produce action. Various approaches
have been used to overcome these problems, some of which include, control of particle size
and lamellarity, altering the lipid composition, lyophilisation, electrosteric stabilization etc..
PROLIPOSOMES 18
One such approach which helped overcome the stability issue associated with
liposome and led to the development of a new drug delivery system is the proliposomes.
Proliposomes are dry, free-flowing granular products composed of drug(s) and
phospholipid(s) which, upon addition of water, disperse to form a multi-lamellar liposomal
suspension. It is one of the most cost-effective and widely used methods for producing
commercial liposome products. It is based upon the intrinsic property of hydrated membrane
lipids to form vesicles on contact with water. Being available in dry powder form, they are
easy to distribute, transfer, measure and store making it a versatile system. Liposomes can
either be formed in vivo under the influence of physiological fluids or can be formed in vitro
prior to administration using a suitable hydrating fluid. The liposomes formed on
reconstitution are similar to conventional liposomes and more uniform in size. The present
review gives a brief overview of preparation, evaluation and application of proliposomes as
novel carrier system.
INGREDIENTS USED IN THE PREPARATION OF VESICULAR SYSTEMS 19
Carrier material
The carrier when used in the proliposomes preparation permits the flexibility in the
ratio of components that incorporated. In addition to this, it increases the surface area and
hence efficient loading. The carriers should be safe and non-toxic, free flowing, poor
solubility in the loaded mixture solution and good water solubility for ease of hydration.
Commonly used carriers are listed; they are sorbitol, mannitol, glucose, lactose, sucrose
stearate. Another polysaccharide that can be used as carrier is maltodextrin .It has minimal
solubility in organic solvent. Thus it is possible to coat maltodextrin. It forms particles by
simply adding surfactant in organic solvent. The use of maltodextrin as carrier in
proliposomes preparation permitted flexibility in the ratio of surfactant and other components
which can be incorporated.
Membrane stabilizers
Cholesterol and lecithin are mainly used as membrane stabilizer. Steroids are
important components of cell membrane and their presence in membrane and their presence
in membrane brings about significance changes with regard to bilayer stability, fluidity and
permeability. Cholesterol is a naturally occurring steroid used as membrane additive. It
prevents aggregation by the inclusion of molecules that stabilize the system against the
formation of aggregate by repulsive steric or electrostatic effects. It leads transition from the
gel state to liquid phase in liposomes system. Phosphatidylcholine is a major component of
lecithin. It has low solubility in water and can form liposomes, bilayer sheets, micelles or
lamellar structures depending on hydration and temperature. Depending upon the source from
which they are obtained they are as named as egg lecithin and soya lecithin. It acts as
stabilizing as well as penetration enhancer. It is found those vesicles composed of soya
lecithin are of larger size than vesicle composed of egg lecithin probably due to the difference
in the intrinsic composition. Cholesterol increases or decreases the percentage encapsulation
efficiency depending on either the carrier materials or its concentration within the formula.
Cholesterol along with the addition of carrier forms homogenous liposomes dispersion rather
than only a carrier which forms a gel. Cholesterol is thus usually included in a 1:1 molar ratio
in most formulations as it is known to abolish the gel to liquid phase transition of liposomes
systems resulting in liposomes that are less leaky. The amount of cholesterol to be added
depends on the carriers. It was found that above certain of cholesterol, entrapment efficiency
decreased possibly due to a decrease in volume diameter.
Organic solvents
Chloroform is an organic solvent which evaporates readily, is convenient to handle
and is a popular solvent used in the preparation of vesicle systems. Methanol is also an
organic solvent which is mostly used as a mixture with chloroform for compounds that are
sparingly soluble in chloroform or methanol alone. The volume ratio of chloroform: methanol
used as an organic solvent is usually 8:2. This mixture was used as the solvent in this study as
it was predicted that most compounds dissolved readily in the combination.
Drug
The drug selection criteria could be based on the following assumptions.
 Low aqueous solubility of drugs.
 High dosage frequency of drugs.
 Short half-life.
 Controlled drug delivery suitable drugs.
 Higher adverse drug reaction drugs.
Nature of encapsulated drug
The main factor in the consideration is the influence of an amphiphilic drug on vesicle
formation. When drug was encapsulated in liposomes, aggregation occurred and was
overcome by the addition of a steric stabilizer. When more drugs is added the increase in its
encapsulation could be the result of saturation of the medium. This suggests that the
solubility of certain poorly soluble drugs can be increased by formulation in liposomes but
only up to a certain limit above which drug precipitation will occur. Increase in drug
concentration showed an increase in both percentage encapsulation efficiency and the amount
of drug encapsulated per mole total lipids upon hydration and formation of liposomes.
METHOD OF PREPARATION 19-29
Some of the commonly used methods employed in the preparation of proliposomes
are discussed below. They include
 Film deposition on carrier method.
 Spray drying method.
 Fluidized bed method.
 Super critical anti-solvent method.
Film deposition on carrier method
This is the original method used by the preparation of proliposomes. It involves
deposition of film of drugs and phospholipids onto a porous, water soluble carrier material.
As seen in figure.2, solution of drug and phospholipid’s in a volatile organic solvent is
introduced drop wise via feed tube onto a bed of carrier material held in a flask of a rotary
flash evaporator under vacuum. At any given time, over-wetting of the matrix is avoided and
subsequent aliquot of organic solution is introduced only when a free flowing powder matrix
is obtained 19. The carriers chosen should have high surface area and porosity so that the
amount of carrier required can be easily adjusted to support the lipids. It also enables high
surfactant to carrier mass ratio in the preparation of proliposomes. Further, being water
soluble they allow rapid formation of liposomal dispersion on hydration and by controlling
the size of porous powder, relatively narrow range of reconstituted liposomes can be
obtained. Some of the carriers utilized include- maltodextrin, sorbitol and microcrystalline
cellulose. The manufacturing procedure however appears to be tedious and difficult to
control, since the operation requires a discontinuous step of solvent addition and evaporation
which is time consuming 20. In order to solve this problem, modified the method wherein the
carrier material was dispersed in organic solution of drug and phospholipid/s in flask of
rotary evaporator, and subjected to vacuum evaporation. The suspension made the lipid
distribution more uniform and efficient and the process is continuous and time saving
compared to the original method 21.
Figure.2 Apparatus for the preparing PLs by flim deposition on carrier method
Spray drying method
The unique feature of spray drying process lies in its ability to involve both particle
formation and drying in a continuous single step, allowing better control of particle
formation. Spray drying is not only limited to aqueous solutions, but can also be used for
non-aqueous systems to prepare particles. This method is mainly used when particles of
uniform size and shape are required and can be easily scaled up it is cost effective and
suitable for large scale production of proliposomes 22-23. As seen in Figure.3, the spray drying
process involves four stages: atomization of the product into a spray nozzle, spray-air contact,
drying of the spray droplets and collection of the solid product 24. Initially liquid dispersions
containing pure lipid or lipids and carrier in organic solvent are prepared and pumped into the
drying chamber. The dispersions are atomized into the drying chamber using a spray nozzle
and are dried in a concurrent air flow which is then collected in a reservoir 25. Major concerns
to spray drying are high working temperatures, shearing stresses and absorption phenomenon
that may lead to thermal and mechanical degradation of the active molecules. This can be
improved by optimizing the operating parameters such as drying air temperature and liquid
spraying rate. Stabilizing adjuvant such as disaccharides, cyclic oligosaccharides and polyols
can also be used to protect the integrity of the active molecules and enhance the efficiency of
hydration by increasing the surface area of lipids 26-27.
Figure.3 Apparatus for the preparing PLs by spray drying method
Fluidised bed method
This method can be employed for the large scale production of proliposomes and
works on the principle of particle coating technology. The carrier material used here can vary
from crystalline powder to non pareil beads. When using beads as carrier material, initial seal
coating is applied to the beads to provide a smooth surface for further coating of
phospholipids. This ensures formation of thin uniform coating of phospholipid around the
core and formation of smaller sized liposomes upon hydration. Solution of drug and
phospholipid in organic solvent is sprayed onto the carrier material through a nozzle. At the
same time, the organic solvent is removed by applying vacuum to the fluid bed. To remove
the trace amount of residual solvent the finished lipid-coated powder/beads can be dried
under vacuum overnight. The method offers following advantages:
 It utilizes film coating technology which is well established and processable.
 Various cores and coating materials are available or easy to prepare.
 It is a cost-effective method to prepare liposomes for drug delivery 28-29.
Super critical anti-solvent method 28-29
Supercritical anti solvent method utilizes Supercritical Carbon dioxide (SCCO2) in the
preparation of proliposomes. SCCO2 is a fluid state of carbon dioxide where it is held at or
above its critical temperature and pressure. Antisolvent technology is widely used in food
industry and was developed to prepare proliposomes because of its lower residual solvents,
simpler steps and mild operation temperatures. As shown in figure.4, the apparatus used in
the preparation of proliposomes include three parts: a sample delivery unit, a precipitation
unit and a separation unit. The sample delivery unit consists of two pumps: one for CO2 and
the other for solution. CO2 is supplied from the CO2 cylinder (1) which is cooled down by a
refrigerator (2) and introduced via a high pressure pump (3) to the buffer tank (4), in which it
is preheated. The drug solution is introduced via HPLC pump (11).The solvent used for
dissolving the drug should be completely miscible with CO2. Opening the valves A and B
allows the entry of solution and CO2 into the vessel through the nozzle (B). As seen in Fig
3B, solution is sprayed through the inner tubule whereas CO2 is sprayed through the outer
tubule of the nozzle. The precipitation unit consists of a vessel (9) heated by an air bath. The
separation unit consists of a separator (13) and a wet gas meter (14). The organic solvent is
separated from SCCO2 in the separator because of lower pressure whereas volumetric flow
rate of CO2 is measured by the wet gas meter. After the temperature and pressure of the
separating vessel reaches the pre-set value, valve A is opened to allow entry of CO2 followed
by opening of valve B allowing the entry of drug solution. SCCO2 and solution are mixed and
diffused into one another rapidly as they are sprayed through the coaxial nozzle. This causes
the solutes dissolved in organic solvent to reach super saturation in a very short period of
time because the solubility of solutes in the organic solvent decreases greatly. As a result, the
proliposomes are precipitated in the vessel. Once the solution is completely utilized, valves A
and B are closed while valve C is opened in order to depressurize the vessel at the operating
temperature. The samples are collected on the filter (8) at the bottom of the vessel. The
pressure, temperature and flow rate of the drug solution need to be optimized to obtain high
drug loading in proliposomes.
Figure.4 Apparatus for preparing proliposomes by Supercritical Anti-solvent method 29
CHARACTERIZATION OF PROLIPOSOMES 30 - 34
Mean particle size and particle size distribution:
Particle size distribution analysis of proliposome determines the physicochemical
behavior of the formulation, such as saturation solubility, dissolution velocity, physical
stability etc. The particle size distribution can be determined by using different particle size
analyzers such as photon correlation spectroscopy (PCS), laser diffraction (LD) and coutler
counter multisizer.
Zeta potential:
Zeta potential is an important parameter in characterization study which indicates the
stability of formulated proliposomes. The suspensions stabilized only by electrostatic
repulsion, a minimum zeta potential of ± 30 mV is required, and if the suspension is
stabilized by combined electrostatic and steric stabilizer a zeta potential of ± 20 mV is
sufficient.
Saturation solubility and dissolution velocity:
Proliposomes have an important advantage over other techniques used for
solubilization that it can increase the dissolution velocity and also the saturation solubility.
The assessment of saturation solubility and dissolution velocity of proliposomes helps in
determining the in-vitro behavior of the formulation.
In-vitro drug release studies-USP paddle method:
An in-vitro drug release study is an integral part of characterization for any drug
delivery system. It is considered an indicator of batch to batch variability associated with
quality control. It can discriminate between various batches for the same formulation
consisting of the same ingredients at various levels. Most interestingly, it can be used as an
indicator for the in-vivo performance of the formulation. There are several factors which can
govern drug release from a polymeric nanoparticulate carrier such as: solubility; diffusion;
desorption; matrix erosion; degradation; and particle size. No standardized methods are
available to study the drug release from nanosized carries.
In -vitro release and permeation studies
In-vitro release and skin permeation studies for proliposomes were determined by
different techniques like Franz diffusion cell, dialysis tubing and reverse dialysis. In case of
dialysis, the prewashed dialysis tubing is used which can be hermatically sealed, the
proliposomes are placed in it and then dialysed against a suitable dissolution medium at a
room temperature. The samples are withdrawn from the medium at suitable interval,
centrifuged and analysed spectrophotometrically (UV, HPLC).
APPLICATIONS OF PROLIPOSOMES 35-55
Proliposomes can be exploited for the following routes of administration
 Parenteral Delivery
For liposomes to be developed for parenteral application, their sterilization is
mandatory. Routinely employed sterilization techniques in Pharmaceutical industry include-
Steam sterilization, γ- irradiation, aseptic manufacturing and filtration sterilization. Terminal
sterilization using steam at 121 ºC may not be suitable for liposomal formulations, since high
temperature may disrupt the liposome architecture due to hydrolysis of lipids, leading to
physical destabilization. γ- Irradiation is also unsuitable for liposomal dispersions, since
radiation causes hydrolysis and accelerates the peroxidation of unsaturated lipids. Aseptic
manufacturing is not commonly used due to the expense and difficulty in validation.
Filtration sterilization of the final product can be challenging due to the structural complexity
of these vesicles and loss of lipids by their non-specific adsorption to filters 35-36.
Proliposomes are well suited for parenteral application of liposomes. The main
advantage associated with proliposomes is that it allows sterilization without affecting the
intrinsic characteristics 36. Besides, they can be stored as sterilized in dry state and can be
hydrated prior to administration to form multilamellar liposomal suspension 37. In addition,
several recent studies have reported that γ- irradiation sterilisation is not as detrimental to
liposomes as previously assumed, particularly when irradiated in the dry state. Since
hydroxyl radicals (resulting from exposure of water to radiation), are a major source of the
free radicals which cause the damage. Thus water content plays a key role in the stability of
liposomes during this process. Being available in dry form, γ- irradiation may be used as a
sterilization technique for proliposomes 38.
 Oral Delivery
Oral drug delivery continues to be the preferred route of administration, but liposomes
have limited success in delivering drugs through oral route 39-40. This is due to the absence of
a stable dosage form for oral delivery and erratic and unpredictable absorption profiles shown
by liposomes. This is due to their inability to retain their integrity at the site of absorption.
Being available as free flowing powder, proliposomes represents the first example of
delivering liposomes into solid dosage form such as tablets or capsules 40. Further, liposomes
are formed on contact with biological fluids at the site of absorption ensuring the retention of
liposome integrity. Proliposomes act as one of the most promising vehicles for enhancing the
dissolution efficiency of poorly soluble drugs. It forms multi-lamellar vesicles on hydration
which ensures higher incorporation of insoluble drugs due to increased hydrophobic volume
within the liposomal lamellae. It also allows conversion of drug from crystalline to
amorphous form 41. The larger particle size of multi lamellar liposomes formed on hydration
ensures lymphatic uptake and improves the bioavailability of drugs undergoing high first pass
metabolism 42. Further, the phospholipid molecules which form the backbone of the bilayer
structure help to enhance the solubility of drug molecule.
 Pulmonary Delivery
Major advantage of liposomes as pulmonary drug delivery system is that they are
prepared from phospholipids which are endogenous to lungs as component of lung surfactant.
Drug encapsulation in liposomes provides modulated absorption, resulting in localized drug
action in the respiratory tract and prolonged drug presence in circulation and reduced
systemic adverse effects 43-44. Drug delivery to the pulmonary route is achieved by three types
of devices namely
 Pressurised Metered Dose Inhalers (pMDI)
As the name suggests it consists of solution or suspension of drugs in liquefied
propellants. Use of Hydro fluroalkanes as non-ozone depleting propellants over CFCs has the
limitation for liposome delivery as they are poor solvents for phospholipids. Proliposomes
help overcome this limitation as they can be suspended in these propellants and serve as
carrier for pulmonary delivery of liposomes through pMDI 45.
 Dry Powder Inhalers (DPIs)
These disperse the drug into the patient’s airstream as a fine powder during inhalation.
Delivering liposomes through DPI have many advantages such as controlled delivery,
increased potency and reduced toxicity, uniform deposition of drugs locally, patient
compliance, stability and high dose carrying capacity. Being available as dry powder form,
Proliposomes are the best alternative for delivering liposomes through DPIs 43-45. It was
developed by spray dried liposome encapsulated dapsone DPI for prolonged drug retention in
lungs to prevent pneumocystis carinii pneumonia. Prolonged drug release of up to 16 hours
was observed in-vitro.
 Nebulizers
Nebulization offers the simplest means, for delivering liposomes to the human
respiratory tract but it is concerned with liposome leakage and drug stability. Use of dry
powder formulations has been suggested to overcome these issues. Lyophilisation and jet
milling may be used to obtain dry powder but tend to have deleterious effect on liposomes
due to the stresses involved in these processes. Thus, proliposomes serve as a stable
alternative for delivering liposomes through nebulization. Besides, the ready formation of an
isotonic liposome formulation in situ from proliposomes seems to offer advantages over other
formulation approaches 43-44.
 Transdermal delivery
Phospholipids, being the major component of liposomal system, can easily get
integrated with the skin lipids and maintain the desired hydration conditions to improve drug
permeation. When proliposomes are applied to mucosal membrane, they are expected to form
liposomes on contact with mucosal fluids whereby the resulting liposomes act as sustained
release dosage form for loaded drugs. Liposomes formed on hydration have the ability to
modulate diffusion across the skin. They do so by fusing with the skin surface and
establishing concentration gradient of the intercalated drug across the skin. Thus they
enhance skin permeation. Also, the vesicle intercalation into the intracellular lipid layers of
the skin results in fluidization and disorganization of the regular skin structure, obviating the
barrier function of the stratum corneum 37-46. Exemestane, a novel steroidal aromatase
inactivator has limited bioavailability of 42% due to poor solubility and extensive first-pass
metabolism. The utilised proliposomes system for transdermal delivery of Exemestane and
found a 2.4 fold increase in bioavailability from proliposomes gel compared to oral
suspension 46. Proliposomes have also been developed for sustained delivery of nicotine 37
and aceclofenac 48 transdermally.
 Mucosal delivery
Proliposomes form vesicular structures (liposomes) in-vivo, triggered by the aqueous
environment found on the mucosal surfaces. Phospholipids present in them have natural
affinity for biological membranes. Besides they are generally nontoxic and non irritant 48.
The presence of drug as molecular dispersion in the bilayers offers improved drug activity.
Further, the difficulties associated with liposomal preparations such as stability and loading
are circumvented because the proliposomes convert to vesicular structures in-vivo, i.e., on the
mucosa. Liposomes formed on hydration with the mucosal fluid, get deposited on the mucosa
as drug reservoirs thereby increasing the drug retention capacity. The significantly higher
mucosal retention of the liposomes, results in higher partitioning of the drug into the mucosa.
This is responsible for prolonged and enhanced drug activity. This led to the utilization of
proliposomes for vaginal and nasal drug delivery 49.
 Vaginal delivery systems are frequently required to treat local fungal infections. The
poor aqueous solubility of antifungal and steroid compounds in conventional
formulations limits their presence as molecular dispersion and consequently affects
the drug concentration at active sites. The association of these lipophilic agents with
the phospholipid molecules of proliposomes makes them excellent carriers to
molecularly disperse the drug 49. Clotrimazole is widely and effectively used for the
treatment of vulvovaginal candidiasis but has low aqueous solubility. Commercially
available conventional Clotrimazole vaginal delivery systems, such as creams, foams,
and gels, are considered to reside the drug for a relatively short period of time at the
targeted site. It was developed by a proliposoms formulation of Clotrimazole and
compared the fungicidal efficacy with the standard ointment in rats. The results
indicated that Clotrimazole containing vaginal proliposomes prolonged drug release
and increased the drug retention into the mucosa. This resulted in higher antifungal
efficacy compared to the standard ointment and in addition it did not affect the
morphology of vaginal tissues confirming the non-toxic and non-irritant nature of the
carrier 55.
 Nasal mucoadhesive delivery has been used to improve local and systemic delivery of
therapeutic compounds 51. It is a promising alternative for systemic administration of
drugs that are poorly absorbed via the oral route 52. Limitations associated with this
route are mucociliary clearance which limits the residence time of drug in the nasal
cavity and lack of sustained release of drugs with short half-life 52-53. Proliposomal
delivery helps to overcome these limitations. Liposomes formed on hydration
decrease the mucociliary clearance of drugs due to their surface viscosity and provide
intimate and prolonged contact between the drug and mucus membrane. Hydration
process of proliposomes plays a role in sustaining the plasma concentration of drugs
with short half-life in systemic circulation 54-55.
 Propranolol is a β blocker which shows rapid absorption when administered
intranasally as an aqueous solution. Due to this, it is eliminated very rapidly from the
systemic circulation needing frequent dosing. The utilised proliposomes for nasal
delivery of propranolol. Sustained plasma concentration of propranolol was obtained
due to the slow hydration process of proliposomes in nasal cavity. It was given by the
Mean hydration time (MHT) of proliposomes which was defined as the difference of
Mean Residence time between liposomes and proliposomes. It was found to be 80.4









 Molecular Formula : C25H22O10
 Molecular Weight : 482.44
 Appearance : Yellow powder
 Density : 1.527 gm/cm3
 pH : 5.5 to 7.0
 Melting point : 230-233 0C
 Solubility : Soluble in DMSO and in ethanol
 Functional Categories : Anti-oxidant, estrogenic and apoptotic agent.
 Stability and storage conditions       : Keep container tightly closed and dry in a
well-ventilated place.
 Incompatibilities : Incompatible with strong oxidizing agent.
 Handling precautions : Provide appropriate exhaust ventilation at
places where dust is formed.
PHARMACOKINETICS:
Silymarin is not soluble in water and is usually administered in an encapsulated
form. Silymarin is absorbed when given orally. Peak plasma concentration is achieved in 6-8
pH. The oral absorption of silymarin is only about 23-47 %, leading to low bioavailability of
the compound; it is administered as a standard extract (70-80 % silymarin). After oral
administration the recovery in bile ranges from 2-3 %. Silybin and the other components of
silymarin are rapidly conjugated with sulfate and glucuronic acid in the liver and excreted
through the bile. The poor water solubility and bioavailability of silymarin led to the
development of enhanced formulations.
2.1.3 DOSE:
Now food silymarin 300mg. Adult: Recommended dose is 140mg 2 – 3 times/day.
2.1.3 MECHANISM OF ACTION:
Silymarin hepatoprotective effects are purportedly accomplished via several mechanisms;
these include:
 Antioxidationt.
 Inhibition of lipid peroxidation.
 Stimulation of ribosomal RNA polymerase and subsequent protein synthesis, leading
to enhanced hepatocyte regeneration.
 Enhanced liver detoxification via inhibition of phase I detoxification.
 Enhanced glucuronidation and protection from glutathione depletion.
 Anti-inflammatory effects, including inhibition of leukotriene and prostaglandin
synthesis, Kupffer cell inhibition, mast cell stabilization, and inhibition of neutrophil
migration.
 Slowing or even reversing of fibrosis by reduction of the conversion of hepatic
stellate cells into myofibroblasts.
 Anticarcinogenesis by inhibition of cycline-dependent kinases and arrest of cancer
cell growth.
 Silymarin is also found to have immunomodulatory effects on the diseased liver.
2.1.4 ADVERSE EFFECTS:
Abdominal bloating, diarrhea, flatulence, loss of appetite, nausea and stomach upset.
2.1.5 DRUG – FOOD INTERACTION:
Food drug interaction mainly involves the interaction of drug with food. Herbs, dairy
products, alcohols and caffeine.
2.1.5 CONTRAINDICATIONS: Hypersensitivity.
2.1.6 PHARMACOLOGICAL ACTION:
Hepatoprotective, immunomodulatory, antioxidant, anti-inflammatory activities
neuroprotective, and antiproliferative effects. It is also used for hypercholesterolemia,






(2R)-2, 3-di (tetradecanoyloxy)propyl) 2-(trimethylazaniumyl) ethyl phosphate.
Chemical Structure:
Molecular Formula : C44H86NO8P
Molecular Weight : 789
Appearance : Cream to yellowish light brown powder
Density : 1.03 to 1.08 gm/cm3
pH : 7
Melting point : 226-230 0C
Solubility : It has low solubility in water.
Functional categories : Natural emulsifier or stabilizer, anti-oxidant, wetting
agent.
Soya lecithin has emulsification and lubricant properties, and is a surfactant. It can be
totally metabolized by humans, so is well tolerated by humans and non-toxic when ingested;
some emulsifiers can only be excreted via the kidneys.
STABILITY AND STORAGE CONDITIONS:
Stable, but light, heat, moisture and air sensitive.
Keep container tightly closed. Store in a cool, well-ventilated area.
INCOMPATIBILITIES:
Incompatible with strong oxidizing agent.
HANDLING PRECAUTIONS:
If overheated, remove source of heat.
APPLICATION IN PHARMACEUTICAL TECHNOLOGY:
It acts as a wetting, stabilizing agents and choline enrichment carrier, helps in
emulsifications and encapsulation, and is good dispersing agent. It can be used in
manufacture of intravenous fat infusions and for therapeutic use.
TPGS (60)






Molecular formula : C35H58O6
Molecular weight                                      : 574.83 g/mol
Appearance : White to light tan waxy solid
pH : 4-10
Melting point : 37 – 41 0C
Solubility : Water soluble (1 g/10 ml)
Functional categories                               : Tocopherol polyethylene glycol 1000 succinate
may be used to create biodegradable polymers
and anti-oxidant, surfactants.
STABILITY AND STORAGE CONDITION:
Keep container closed. Protect from contamination.
INCOMPATIBILITY:
Reacts with strong oxidizing agents and alkali.
HANDLING PRECAUTIONS:
Avoid keeping TPGS with oxidizing materials.
APPLICATION IN PHARMACEUTICAL TECHNOLOGY:
TPGS has been widely used for its emulsifying, dispersing, gelling, and solubilizing
effects on poorly water-soluble drugs. It can also act as a P-glycoprotein (P-gp) inhibitor and
has been served as an excipient for overcoming multidrug resistance (MDR) and for








Molecular formula : C27H46O
Molecular weight                                      : 386.67 g/mol
Appearance : White or faintly yellow, almost odourless, pearly
leaflets, needles, powder or granules.
pH                                                              : 7.35 -7.45
Melting point : 147-150 0C
Solubility : Soluble in acetone and vegetable oils
Functional categories                               : Cholesterol may be used to emulsifying
agent, Emollient.
STABILITY AND STORAGE CONDITION:
It is stable, and should be stored in a well- closed container and protected from light.
SAFETY:
It is generally regarded as an essentially non- toxic and non- irritant material at the
levels employed as an excipients
HANDLING PRECAUTIONS:
Rubber or plastic gloves, eye protection and a respirator are recommended.
APLICATION IN PHARMACEUTICAL TECHNOLOGY:
It is used in cosmetics & topical pharmaceutical formulations as an emulsifying agent.
It imparts water absorbing power to ointments. It is the major sterol of higher animals, & is






Molecular formula : C6H14O6
Molecular weight : 182.17 g/mol
Appearance : White crystalline powder
pH : 5.0 – 7.5
Melting point : 94-96 0C
Solubility : Soluble in water and slightly soluble in methanol
Functional categories : Sorbitol is used as substitute for sugar, laxative.
STABILITY AND STORAGE CONDITION:
It is stable stored in a well closed container at room temperature
SAFETY:
It is generally regarded as an essentially non- toxic and non- irritant material at the
levels employed as an excipients.
HANDLING PRECAUTIONS:
If overheated it melts avoid. Respirator recommended
APPLICATION IN PHARMACEUTICAL TECHNOLOGY:
Sorbitol often is used in modern cosmetics as a humectants and thickener. It is also
used in mouthwash and toothpaste. Some transparent gels can be made only with sorbitol,
because of its high refractive index.
LITERATURE REVIEW
LITERATURE REVIEW
Theresa Kott, et al (1994) 63 investigated the hepatoprotective activity by using
animal (rat) with acetylsalicylic acid (150 mg/kg b.w.per os daily) for six weeks. Half of the
rats received silymarin (17.5 mg/kg b.w. per os daily) in the last three weeks of the
experiment. It was found that administration of acetylsalicylic acid led to the signs of hepatic
damage. Administration of silymarin diminished the extent of the hepatic damage.  The
obtained results suggest that silymarin be administered to the patients undergoing long-term
treatment with non-steroidal anti-inflammatory drugs in order to prevent hepatic damage, but
further studies are needed to elaborate on the clinical aspects of silymarin treatment in those
patients.
Om Parkash Katare, et al (2005) 64 studied synergistic hepatoprotective effect of
silymarin with phospholipids when it is engaged in microspheres so as to passively target it to
liver and to compare these silymarin formulations with silymarin solution. Various silymarin
loaded lipid emulsions were formulated which includes: formulation A  soyabean oil as an
internal oily phase, soya lecithin as surfactant and tween 80 as co-surfactant; formulation B
which was same as formulation A but was filtered through 0.45 micro membrane filter and
finally steam sterilized for intravenous administration; formulation C containing soyabean oil
as an internal oily phase, soya lecithin as surfactant, tween 80 and propylene glycol as
cosurfactant/ cosolvent.while comparing to three formulations , the best formulation was
found formulation B , it may confirmed by practically.
Rajesh Agarwal, et al (2006) 65 studied silymarin consists of a family of flavonoids
(silybin, isosilybin, silychristin, silydianin and taxifoline) commonly found in the dried fruit
of the milk thistle plant Silybum marianum. Although silymarin’s role as an antioxidant and
hepatoprotective agent is well known, its role as an anticancer agent has begun to emerge.
Extensive research within the last decade has shown that silymarin can suppress the
proliferation of a variety of tumor cells (e.g., prostate, breast, ovary, colon, lung, bladder);
this is accomplished through cell cycle arrest at the G1/S-phase, induction of cyclin-
dependent kinase inhibitors (such as p15, p21 and p27), down-regulation of anti-apoptotic
gene products (e.g., Bcl-2 and Bcl-xL), inhibition of cell-survival kinases (AKT, PKC and
MAPK) and inhibition of inflammatory transcription factors (e.g., NF-κB). Silymarin can
also down-regulate gene products involved in the proliferation of tumor cells (cyclin D1,
EGFR, COX-2, TGF-‚, IGF-IR), invasion (MMP-9), angiogenesis (VEGF) and metastasis
(adhesion molecules). The anti- inflammatory effects of silymarin are mediated through
suppression of NF-κB-regulated gene products, including COX-2, LOX, inducible iNOS,
TNF and IL-1.
Sarala yanamandra, et al (2014) 66 Objective of the present study was to develop a
proliposomal formulation to decrease the hepatic first-pass metabolism of a highly
metabolized drug. Lovastatin was chosen as the model drug. Proliposomes were prepared by
mixing different ratios of phospholipids such as soy phosphatidylcholine (SPC),
hydrogenated egg phosphatidylcholine (HEPC) and dimyristoyl phosphatidylglycerol
(DMPG) individually with drug and cholesterol in an organic solvent.In- vivo studies were
carried out in male Sprague–Dawley rats. Following single oral administration of the selected
formulation (F9), a relative bioavailability of 162% was achieved compared to pure
lovastatin. The study demonstrated that proliposomes can be used as a drug delivery system
to decrease the hepatic first-pass metabolism.
Grishma M Patel, et al (2017) 67 present work was to apply quality by design (QbD)
principles for the development of proliposome of poorly soluble lopinavir (LPV). The
patient-centric quality target product profile (QTPP) was defined and critical quality
attributes (CQAs) earmarked. Risk assessment studies were carried out to identify the
probable risks affecting the CQAs of the product. On the basis of preliminary study,
lipid:drug ratio and amount of carrier were selected as critical material attributes (CMAs) and
were optimized by face centered central composite design. Liposome vesicle size, drug
entrapment efficiency and % drug release after 60 min were selected as CQAs and
mathematical relationship between CQAs and CMAs was derived using multiple linear
regression analysis.  Solid state characterization studies (DSC, SEM  and X-RD) were
performed for optimized proliposome, suggested transformation of crystalline to amorphous
form. Oral bioavailability study in wistar rats revealed that LPV proliposome exhibited 2.24
and 1.16 fold higher bioavailability than pure LPV and available commercial formulation of
LPV/RTV (lopinavir + ritonavir), respectively. Stability study of the optimized LPV loaded
proliposome was performed as per ICH guideline and was found to be stable for period of
6 months. Overall results of the study indicate that the proliposome offers advantages of
enhanced oral bioavailability for poorly soluble.
D. V. Gowda, et al (2016) 68 investicate liposomes are employed broadly on all the
novel drug delivery in current years. Liposomal suspensions were developed and they
resulted in limited shelf life and poor stability problems on long term storage, these problems
are overcome by Proliposomes. Proliposomes were discovered by Payne et al in 1986.
Proliposomes are free flowing granular product composed of drug and phospholipid
precursors which on hydration lead to liposomes .This paper reviews different aspects related
to liposomes, proliposomes their method of preparation, comparison between liposomes and
proliposomes, characterization of proliposomes, applications and major focus is made on
Proliposomes employed for different routes of administration.
Osama A Badary, et al (2005) 69 evidenced cisplatin-induced nephrotoxicity and
confirm the antioxidant potential of silymarin. The effect of silymarin (NAR), a naturally
occurring citrus flavanone, on the acute nephrotoxicity produced by cisplatin (7 mg/kg, i.v.)
was investigated in the rat. Oral administration of NAR (20 mg/kg/day) for 10 days, starting
5 days before cisplatin single i.v. injection, produced significant protection of renal function.
NAR reduced the extent of cisplatin-induced nephrotoxicity, as evidenced by significant
reduction in serum urea and creatinine concentrations, decreased polyuria, reduction in body
weight loss, marked reduction in urinary fractional sodium excretion and glutathione S-
transferase (GST) activity, and increased creatinine clearance. Cisplatin-induced alterations
in renal cortex lipid peroxides and GST activity were markedly improved by NAR. Cisplatin-
induced alterations in renal cortex antioxidant defense system were greatly prevented by
NAR. In cisplatin-NAR combined treatment group, antioxidant enzymes namely superoxide
dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) were significantly
increased to 54.5, 30.3 and 35.6%, respectively compared to cisplatin treated group. Platinum
renal content was not affected by NAR treatment. The results provide further insight into the
mechanisms of cisplatin-induced nephrotoxicity and confirm the antioxidant potential of
NAR.
Yingjun Liao, et al (2008) 70 studied to explore the optimal combination of agents
used along with cisplatin for protection of hepatotoxicity. The objective of this study was to
explore the optimal combination of agents used along with cisplatin for protection of
hepatotoxicity. Animal experiment was carried out based on the orthogonal design L8 (27)
setting seven factors with two different levels of each and eight groups of mice were needed.
The agents tested in this study were zinc, selenium, fosfomycin, sodium thiosulfate (STS), N-
acetyl-cysteine (NAC), methionine and taurine. Mice were supplemented by gavage with
various combinations of agents as designed in the orthogonal table once a day for nine days
beginning two days before cisplatin administration. 3.5 mg/kg body weight of cisplatin was
given intraperitoneally once a day for five days simultaneously. After cessation of cisplatin
administration, the agents were supplemented continuously for two days. Activities of alanine
aminotransferase (ALT) in serum, levels of glutathione (GSH) and malondialdehyde (MDA)
in liver were analyzed after cessation of supplementation. Results showed zinc, fosfomycin
and methionine were the effective factors for protection of weight loss; fosfomycin and
methionine were the effective factors for prevention of decreased liver ratio; selenium,
fosfomycin and STS were the effective factors for prevention of increased ALT activities in
serum. On the other hand, methionine was the only effective factor for prevention of
decreased GSH levels in liver; zinc, selenium and fosfomycin were the effective factors for
prevention of increased MDA levels in liver. Based on the data observed in this study, the
optimum combinations of agents were selenium, fosfomycin, methionine and taurine, and
zinc, selenium, STS and methionine. In conclusion, each agent used in this study could play a
beneficial role for prevention of cisplatin hepatotoxicity; however, none could play the
crucial role. The potentiated actions for prevention of cisplatin hepatotoxicity could be
achieved via combined use of these agents.
Abdelmeguid, et al (2010) 71 suggested that silymarin possess protective effects
against cisplatin hepatotoxic action in animal models. The benefit of silymarin, a plant
extract with strong antioxidant activity against hepatotoxicity induced by cisplatin in rats was
investigated in this study. Cisplatin is one of the most effective chemotherapeutic drugs, yet
it alone does not achieve a satisfactory therapeutic outcome and at high doses it can produce
undesirable side effects. Five equal-sized groups (18 rats each) of male Sprague dawley rats
[control, vehicle; cisplatin; silymarin 2 hrs after cisplatin injection; and silymarin 2 hrs
before cisplatin injection] were used. Histopathological and ultra-structural observations of
livers were carried out using light and electron microscopy. Results documented that
cisplatin produced behavioral, external features animal changes, as well as hazard
pathological picture changes in liver where most hepatocytes appeared diminutive with
vacuolated cytoplasm, sinusoids dilated and organelle disorganized. These results revealed
that cisplatin may be toxic and terminates in complex liver damage. Administrations of
silymarin 2 hrs after cisplatin significantly increase the body weight returning it to normal,
yet it failed in complete protection against the pathological alteration caused by cisplatin.
Pretreatment with silymarin 2 hrs before cisplatin significantly decreased the pathological
changes induced by cisplatin and appeared highly protective. These results suggested that
silymarin possess protective effects against cisplatin hepatotoxic action in animal models.
Since, no significant toxicity of silymarin is reported in human studies, this plant extract can
be used as a dietary supplement by patients taking anti-cancerous medications and might
serve as a novel combination agent with cisplatin since it plays a significant role in reducing
its toxicity.
Marija Petrovic, et al (2016) 72 evidenced that cisplatin can activate in cancer cell,
the mechanism of resistance and clinical toxicities. Cisplatin (cis-Diamminedichloroplatinum
II) is one of the most important chemotherapeutic agents widely used in treatment of many
types of solid cancer. Accumulating evidence suggests that the cytotoxic activity of cisplatin
involves both nuclear and cytoplasm component, but its biochemical and molecular
mechanisms of action are still unclear. Its mode of action is linked to the ability of cisplatin to
interact with purine bases on the DNA, causing DNA damage, interfering with DNA repair
mechanisms and inducing apoptotic cell death in cancer cells. The major limitations in the
clinical application of cisplatin are the numerous side effects and the development of cisplatin
resistance by tumors. Mechanisms that can explain cisplatin resistance include the reduction
in drug accumulation inside the cell, higher concentration of glutathione and
metallothioneins, faster repair of cisplatin adducts and modulation of apoptotic cell death in
various cells. In this article we review the pathways that cisplatin can activate in cancer cell,
the mechanisms of resistance and clinical toxicities. A deep knowledge of mechanisms of
action may lead to design of more efficient platinum-based antitumor drugs and provide new
therapeutic strategies in cancer treatment.
AIM AND OBJECTIVE
AIM AND OBJECTIVE
Silymarin is one of the best known hepatoprotective drugs obtained from the seeds of
Silybum marianum L., Family: Asteraceae or Compositae. Since ages, this plant, also known
as milk thistle, is being used as a herbal cure for liver and biliary tract diseases. This plant has
been known to safeguard and also regenerate the liver cells in various diseases affecting liver
such as cirrhosis, jaundice and hepatitis. It exhibits strong anti-oxidant action via free radical
scavenging activity and inhibits lipid peroxidation. It also prevents the entry of harmful
toxicants such as heavy metals, pesticides, alcohols, medicines, CCL4 etc. in liver, thereby
protecting the liver cells from further damage.
Silymarin is a mixture of flavonolignans, which comprises of silybin, isosilybin,
silydianin and silychristine. It exerts hepatoprotective action at an oral dose of 240-800
mg/day in two or three divided dose. The water solubility of the drug is very poor (0.04
mg/ml). Oral administration of silymarin  is rapidly absorbed with a tmax 2 to 4 hours and its
t1/2 is 6 hours. Only 20 – 50 percent of silymarin is absorbed from the gastrointestinal tract.
Therefore, absorption of silymarin from the gastrointestinal tract is low that leads poor
bioavailability.
The Silymarin poor bioavailability is mainly due to extensive metabolism, poor
aqueous solubility and rapid excretion through urine and bile as well as low permeability
across intestinal epithelial cells. The short half-life, poor bioavailability and high frequency
of administration of silymarin, thus nesessery for the development of nanoparticulate drug
delivery systems.
Nanotechnology based drug delivery systems improve the aqueous solubility; enhance
the dissolution, permeation and bioavailability of poorly soluble drugs. Many hepato
protective drugs offer challenging problems in drug formulation and it is generally associated
to poor solubility and dissolution characteristics and thus leads to low bioavailability. In order
to enhance these characteristics, preparation of proliposomes has been achieved using film
deposition method.
The aim of the present investigation is to formulate and optimize TPGS modified
silymarin proliposomes by film deposition method in order to overcome its poor dissolution
behavior, minimize physical instability problems, prolonging the circulation time of the
entrapped drug and to improve oral absorption, altering its organ distribution as well as
metabolic instability followed by improve its therapeutic potential in terms of
hepatoprotective activity.
So the objective of the present study is to carry out formulation and evaluation of
TPGS modified proliposomes of silymarin by using suitable polymer to improve its
solubility, dissolution, permeation  bioavailability and to increase it biological half-life
followed by evaluation of its therapeutic potential in terms of hepatoprotective activity using
suitable animal model.
The following objectives are outlined to achieve the aim and need of the study:
 To select appropriate drug and polymers
 To perform Pre-formulation studies
 To develop the preparation of proliposomes.




The aim of our work is to formulate and evaluate the TPGS stabilized proliposome of
the drug silymarin by using different polymers and surfactants. The following experimental
protocol is therefore designed to allow a systemic approach to the study.
 Literature survey.




 Melting point determination.
 Drug and polymer interaction study.
 FT-IR
 Formulation of proliposome by film deposition method and lyophilisation of the
prepared proliposomes.
 Evaluation of prepared proliposomes.
 Drug content.
 Particle size analysis.
 Poly dispersity index.
 Zeta potential analysis.
 Solubility studies
 In-vitro drug release.







Table: 1. List of materials used.
S.NO NAME COMPANY
1. Silymarin Himedia, Mumbai.
2. Soya lecithin Glen mark Generic Limited, Mumbai.
3. TPGS Ludwigshafen, Germany.
4. Hydrochloric Acid Himedia, Mumbai.
5. Potassium Dihydrogen Phosphate Himedia, Mumbai.
6. Disodium Hydrogen Phosphate Himedia, Mumbai.
7. Distilled water Leo scientific, Erode.
8. α-Tocopherol Loba Pvt., Mumbai.
9. Sodium chloride Nice Chemicals, Coimbatore.
10. Nitro cellulose membrane Loba Pvt., Mumbai.
11. Cisplatin Alkem, Mumbai.
12. Cystone Himalayas, India.
INSTRUMENTS
Table: 2. List of instruments used.
S.NO NAME COMPANY
1. Melvern Zetasizer Malvern Nano ZS-90, UK.
2. Freeze Dryer Lyodel (Delvac), India
3. Cold centrifuge Remi, Mumbai.
4. Deep freezer Blue Star
5. Research centrifuge Remi
6. Rotary shaker Genuine
7. Hot air oven Genuine
8. Refrigerator Godrej
9. Analytical balance Shimadzu, Japan
10. IR- Spectrometer Ftir-8400 S Shimadzu, Japan
11. PH-meter (Digital) Li 613,Elico
12. UV spectrophotometer UV 1800 Shimadzu, Japan
13. BTS 350 Semiautomatic analyser Bio system, Spain




1. Procurement of drug, polymers and excipients for formulation development.
2. To carry out preformulation study.
Preformulation testing is an investigation of physical and chemical properties
of a drug substance alone and when combined with excipients. The overall objective
of preformulation testing is to generate information useful to developing the stable
and bio-available dosage form obviously, the type of information needed will be
depends on the dosage form to be developed. The use of preformulation parameter
minimizes the chances in formulation and acceptable, safe, efficacious and stable
product and at same time provides the basis for optimization of the drug product
quality.
3. Drug and polymer interaction studies: Infrared spectroscopy.
4. To formulation of proliposomes:
Film deposition method. Lyophilization of the prepared proliposomes.
 Pre-formulation study
 Solubility studies
 Characterization of the drug, excipients and its mixture using melting point
determination, UV spectroscopy and Infrared spectroscopy.
 Preparation of calibration curve of drug in 0.1 N Hcl (pH 1.2) and phosphate
buffer  (pH 7.4)
 Compatibility study of drug, polymer and its mixture
 Preliminary development of trial batches to establish the required profiles.
 Evaluation of proliposome formulations.
 Physical evaluation: Morphology and surface topography of the formulation
using Particle size analysis, Poly dispersity index, Zeta potential and IR study.





Based on the composition given in table. 7, using film deposition method, by using
different stabilizers like soya lecithin, cholesterol, TPGS and carrier like sorbitol, in entire
formulation drug, stabilizers concentration are constant. Only TPGS differ in formulations.
Carriers sorbitol taken in a round bottom flask. Then silymarin powder (1 gm), soya lecithin
(2 gm) and cholesterol (2 gm) added according to the formula. It was dissolved by addition of
chloroform. Further to make slurry, chloroform added.  The round bottom flask was fitted
and the solvent was evaporated at 60 rpm under reduced pressure at a temperature of 45±2
°C, until the product become free flowing, dry condition. After that they obtained product
were dried overnight at room temperature in a desiccators under vacuum. The obtained final
preparation of proliposomes was stored in a sealed container at 5 °C and kept it for evaluation
process.
LYOPHILIZATION OF FORMULATIONS:
The proliposome formulations were freeze dried to increase the shelf life and to study
the dissolution behavior. 1 % mannitol was added to each formulation as a cryoprotectant at
the time of lyophilization. Virtis freeze drier is used for lyophilization of proliposomes. At
first the sample was kept overnight in deep freezer at -70 °C  and then sample was kept in
Virtis freeze drier for two days at -50 °C at 2 millitorr.
EVALUATION OF PROLIPOSOME:
PARTICLE SIZE DISTRIBUTION:
The particle size analysis of different formulations of proliposome was carried out
using Microtac Blue wave particle size analyzer. Before measurement of the samples, they
have to be diluted with de-ionized water to obtain a suitable concentration for measurement.
The results obtained for particle size distributions were used to confirm the formation of nano
- sized particles.
ZETA POTENTIAL ANALYSIS:
The particle charge was one of the most important parameter in assessing the physical
stability of proliposome. The large numbers of particles were equally charged, then
electrostatic repulsion between the particles was increased and thereby physical stability of
the formulation was also increased. Typically, the particle charge of colloidal system was
measured as zeta potential measured via the electrophoretic mobility of the particles in an
electrical field. Zeta potential analysis of prepared proliposome formulation was carried out
using Malvern Zetasizer (Malvern instruments). Before measurement the samples were
diluted with de-ionized water and conductivity was adjusted by addition of sodium chloride.
FOURIER TRANSFORM INFRA- RED SPECTROSCOPY:
FT- IR spectra were recorded on the sample prepared in KBr disks (2 mg sample in
200 mg KBr disks) using Shimadzu Fourier Transform Infra-Red spectrometer. The samples
were scanned over a frequency range 4000-400 cm-1.
RE-DISPERSIBILITY & PERCENTAGE DRUG CONTENT DETERMINATION:
The prepared proliposomes were analyzed for drug content by UV spectroscopic
method. Different batches of proliposome equivalent to 10 mg of silymarin weighed
accurately and dissolved in 10 ml ethanol. The stock solutions were diluted with distilled
water and analyzed by UV spectroscopy at 287 nm.
SATURATION SOLUBILITY STUDIES:
The saturation solubility studies were carried out for both the unprocessed pure drug and
different batches of lyophilized proliposomes. 10 mg of unprocessed pure drug and
proliposome equivalent to 10 mg of silymarin was weighed and separately introduced into 25
ml stoppered conical flask containing 10 ml distilled water. The flasks were sealed and
placed in rotary shaker for 24 hours at 37 °C and equivalent for 2 days. The samples were
collected after the specified time interval and it is filtered and analyzed. The samples were
analyzed using UV spectrophotometer at 287 nm.
IN-VITRO DRUG RELEASE STUDIES:
The in- vitro release of silymarin drug  and its proliposome formulation was carried
out in USP dissolution test apparatus using paddle method at a rotation speed of 50 rpm. The
dissolution profile was carried out in freshly prepared acidic buffer (pH 1.2) and also in
phosphate buffer (pH 7.2) 10 mg of pure drug and proliposome containing 10 mg of
silymarin equivalent was taken and placed in dissolution medium. The volume and
temperature of dissolution medium were 900 ml and 37.0 ± 0.2 °C, respectively. Samples
were withdrawn at fixed time intervals and were filtered. The filtered samples were analyzed
at 287 nm using Shimadzu UV-Visible spectrophotometer. The results obtained for different
proliposome formulations were compared with the dissolution profile of unprocessed drug.
PERMEATION STUDIES:
Permeation study was carried out for both unprocessed drug and different
proliposome formulations using cellulose nitrate membrane. The membrane was attached to
the franz diffusion cell and then it was dipped in a beaker containing phosphate buffer pH
7.2. The pure drug sample and equivalent quantity of lyophilized proliposome were weighed
and placed in the different diffusion cell containing the specific quantity of buffer. The
samples were withdrawn at specific time intervals in 10 minutes and replaced with fresh
buffer solution. Finally the samples were analyzed using UV spectrophotometer at 287 nm.
PHARMACOLOGICAL ACTIVITY OF PROLIPOSOME FORMULATIONS
HEPATOPROTECTIVE ACTIVITY
This study was approved by animal ethical committee from Nandha College of
pharmacy. The animal ethical committee approval number is NCP/IPEC/2015-16-04.
Albino Wister strain rats were divided into five groups of six each. CIS-toxicity was
induced by a single dose intraperitoneal injection (i.p.) of Cis (i.p., 7 mg/kg b.w.).
Group I: (Control group) animal served as normal control.
Group II: (CIS treated group) rats received a single dose of cisplatin i.p on fifth day of the
experiment at a dose of 7 mg/kg 73.
Group III: (CIS-NAR) rats of this group were administrated with naringenin (10 mg/kg i.p;
once daily) for 9 days and on 5th day CIS (7 mg/kg b.w) was injected by i.p route. 74
Group IV: (CIS-SILY) rats of this group were administered with silymarin (10 mg/kg) for 9
days and on 5th day CIS was injected by i.p at a dose of 7 mg/kg.
Group V: (CIS-SF2) rats of this group were administered with SF2 (10 mg/kg i.p; once
daily) for 9 days and CIS at a dose of 7 mg/kg was injected by i.p. on the fifth day of the
treatment. 75
At the end of the experiment, rats were euthanized under light anesthesia with diethyl
ether; rats were sacrificed by cervical decapitation. For biochemical assays, blood samples
were collected and serum was separated by centrifugation at 2500 rpm for 15 mins and
analyzed for various biochemical parameters. Total bilirubin and direct bilirubin was
evaluated by Jendrassik & Grof’s Method 76. Triglycerides activity of serum was tested by
the method defined by Glycrokinase peroxidase. Total cholesterol activity was evaluated in
accordance with the assay of CHOD-PAP. Albumin and total protein was evaluated by biuret
method 77. AST, ALT and ALP activities were assessed in serum with commercially available
kits (IFCC) by using an auto analyze 78; livers were excised, rinsed clean in saline and




Silymarin is BCS Class – II drug with low solubility and high permeability. Thus, it
was challenging to enhance the solubility and dissolution rate of silymarin particles in an




The sample of silymarin was evaluated by physical character and by determining the
melting point. The Ultra-violet (UV) and FT-IR absorption spectrum of pure silymarin was
recorded, which was compare and matched with IP reference spectra.
PHYSICAL OBSERVATION:
Physical observation of the drug revealed that silymarin is yellow powder.
SOLUBILITY STUDIES:
Silymarin is insoluble in water (0.04 mg/ml) and slightly soluble in dimethyl
sulfoxide, and dimethyl formamide.
MELTING POINT DETERMINATION:
The melting point of Silymarin was found to be 234 °C and it was matched with
literature, which assured the identity of the received sample.
ULTRA-VIOLET (UV) ABSORPTION SPECTRA:
The silymarin was analyzed by spectrophotometrically in between 200 nm – 400 nm.
The maximum absorbance (λ max) was found at 287 nm which was used for quantitative
analysis. The overlay spectrum of silymain was mentioned in figure.5.
Figure.5: Overlay Spectrum of Silymarin.
PREPARATION OF STANDARD CURVE OF SILYMARIN:
Standard curve in 0.1 N HCl & phosphate buffer (pH 7.2):
The standard curve was prepared by using various concentrations versus absorbance
at 287 nm. The calibration curve was found linear at different concentration at range in 10 –
100 μg/ml.
From the below data (Table. 3) it was observed that the drug obeys beer’s law in
concentration range of 10 -100 μg/ml in 0.1 N HCl. The slope is 0.0149, the correlation
coefficient is 1.009 it follows fit curve since r2 is around 1.
Table. 3: Standard curve of silymarin in 0.1N HCl











Figure.6: Standard curve of silymarin in 0.1N HCl.




























From the below data (Table. 4) it was observed that the drug obeys beer’s law in
concentration range of 10 -100 μg/ml in pH 7.2 phosphate buffer. The slope is 0.0287, the
correlation coefficient is 1.002 it follows fit curve since r2 is around 1.
Table. 4: Standard curve of silymarin in phosphate buffer











Figure 7: Standard curve of silymarin in phosphate buffer.




























DRUG AND POLYMER COMPATIBILITY STUDY:
FOURIER TRANSFORM INFRA RED SPECTROSCOPY:
FTIR Spectroscopy was used to study the possible interaction between pure drug and
polymers. The FT-IR spectra of pure silymarin, soya lecithin, cholesterol, sorbitol, TPGS and
physical mixture of the drug were recorded. The characteristic peaks for silymarin can be
observed. Similar peak were seen in physical mixture of silymarin and polymers. There was
no discrimibile shift/disappearance/appearance of peaks in combined spectra that indicated
good drug – polymer compatibility and no chemical interaction between silymarin and
polymers. Hence, all the polymers were found suitable for development of the proliposome.
The values are representated in the Table. 5 and Table. 6.
Figure.8: FTIR spectrum of silymarin.
Figure.9: FTIR spectrum of soya lecithin.
Figure.10: FT-IR spectrum of cholesterol.
Figure.11: FTIR spectrum of TPGS.
Figure.12: FTIR spectrum of sorbitol.
Table. 5: Interpretation of IR spectrum of silymarin, soya lecithin, cholesterol, sorbitol
and TPGS.
Transition IR Range(cm-1)
Absorption wave number (cm-1)








































































































Figure.15: FTIR spectrum of physical mixture of silymarin formulation 1.
Figure.16: FTIR spectrum of physical mixture of silymarin formulation 2.
Table. 6: Interpretation of IR spectrum of silymarin proliposome formulation physical
mixtures of SF1 and SF2.
Transition IR Range (cm-1)




























1760 - 1665 - 1735.99 1737.92
-C=C- Stretching
Alkenes










1470 - 1450 1462.09 1469.81 1462.09
C-H Rocking
Alkanes














Silymarin proliposomes was prepared by film deposition method using different
polymers such as soya lecithin, cholesterol, sorbitol and TPGS respectively. The polymers
were selected based on literature review and preformulation studies. The ratio of silymarin
proliposome formulations are representated in Table.7.
Table. 7: Composition of drug loaded using different polymers.
LYOPHILIZATION:
The lyophilized proliposomes was performed to increasing the stability. The prepared
silymarin proliposomes was lyophilized using freeze dryer at -70 °C for 3 days. Then vacuum
was applied. 1 % mannitol solution was added as a cryoprotectant. Degassing was carried out
in between to prevent explosion.
EVALUATION OF PROLIPOSOMES:
PARTICLE SIZE AND POLY DISPEERSITY INDEX:
The particle size distribution has most important characteristics affecting the in-vivo
fate of proliposomes. The particle size was measured by Malvern particle size analyzer. The
proliposomes mean particle size ranges from SF1 (100.6nm) and SF2 (80.52nm) for without
stabilizer and with stabilizer respectively as shown in Table. 8.
Polydispersity index gives degree of particle size distribution and promotes the
physical stability of proliposomes. The ranges of the formulations SF1 and SF2 from 0.265
and 0.284 respectively. The formulation SF2 showed lowest particle size (80.52nm) that











1. SF1 1 2 2 5 -
2. SF2 1 2 2 5 0.5
Table. 8: Particle size and poly dispersity index of proliposomes
S.No Formulations Average Particle size (d.nm) Poly dispersity index
1. SF1 100.6 ± 0.19 0.265 ± 0.07
2. SF2 80.52 ± 0.11 0.284 ± 0.03
Mean of three observation ± SD.
Figure.17: Particle size distribution and poly dispersity index of proliposomes SF1.
Figure.18: Particle size distribution and poly dispersity index of proliposomes SF2.
ZETA POTENTIAL ANALYSIS:
The determination of the zeta potential parameter (properly related to the double
electric layer on the surface of colloidal particles) of a proliposomes is an essential as it
provides an indication about the physical stability of proliposomess. Extremely positive or
negative zeta potential values cause larger repulsive forces, whereas repulsion between
particles with similar electric charge prevents aggregation of the particles and thus ensures
easy redispersion. In the case of combined electrostatic and steric stabilization, a minimum
zeta potential of ± 20 mV is desirable. In the study of zeta potential of proliposomes
formulations SF1 and SF2 was found to be in the range of SF1 (-18.6 mV) and SF2
(-4.75 mV) respectively, which indicates good physical stability of proliposomes. The zeta
potential graphs are presented in Figures 19 and 20.
Table. 9: Zeta potential of proliposomes.
S.No Formulations Zeta potential (mV)
1. SF1 -18.6
2. SF2 -4.75
Figure.19: Zeta potential of proliposome SF1.
Figure.20: Zeta potential of proliposome SF2.
FOURIER TRANSFORM INFRA RED SPECTROSCOPY:
The FT-IR analysis was used to evaluate the possible intermolecular interaction
between silymarin and the excipients. The FT-IR spectra of formulated lyophilized were
recorded. Due to similarities in molecular structure of soya lecithin, cholesterol, sorbitol and
TPGS showed similar absorption bands, in which the IR spectra of formulation showed all
the characteristics peaks without any markable change in their position after successful
lyophilized proliposome, it indicate there is no chemical interaction between silymarin, soya
lecithin, cholesterol, sorbitol and TPGS in proliposomes. In proliposome formulation (SF2), a
characteristic peak of silymarin was observed. The values are representated in the Table.10.
Table.10: Interpretation of IR spectrum of proliposome formulations of SF1 and SF2.




3500 - 3200 3504.77 – 3363.97 3483.56 – 3331.18
C-H Stretching alkenes 3100 - 3000 3101.64 – 3032.20 3119.00
C-H Stretching alkanes 3000 – 2850 2918.40 – 2856.67 2891.39, 2874.03
HC≡CH Stretching
alkynes
2260 - 2100 2164.20, 2115.98 2266.43, 2164.20
C=O Stretching
carboxylic acid
1760 - 1690 1739.85 1741.78
-C=C- Stretching alkenes 1680 - 1640 1639.55 1643.41
C-C Stretching aromatic 1500 - 1400 1458.23 1458.23
C-H Rocking alkanes 1370 - 1350 1356.00 1348.29
C-O Stretching alcohols
ester
1320 – 1000 1107.18 1111.03
=C-H Bending alkenes 1000 - 650 995.30 – 740.69 950.94 – 773.48
Figure.21: FT-IR spectrum of proliposome silymarin formulation 1.
Figure.22: FTIR spectrum of prolioposome silymarin formulation 2.
DRUG CONTENT DETERMINATION:
In proliposome formulation the drug particles were reduced to nano size. During the
formulation, the drug content of silymarin proliposome formulations was found to be in the
range of 95.49, 99.61 respectively, which was found to be within the range of ± 5% of the
theoretical claim. The results showed the all proliposome formulations have shown the
presence of high drug content low standard deviation and loss of drug was lower during
preparation process. It indicates that the drug is uniformly dispersed in the powder
formulation. Therefore, the method used in the study appears to be reproducible for
preparation of proliposomes. The results are as given in Table. 11.
Table. 11: Percentage drug content of all lyophilized silymarin proliposome
formulations.
S.No Formulation code % drug content
1. SF1 95.49 ± 0.63
2. SF2 99.61 ± 0.32
Mean of three observations ± SD.



























The solubility profile of silymarin proliposome formulations increases dissolution
velocity and saturation solubility, size reduction leads to increase in dissolution rate. The
solubility of silymarin showed 19.67 μg/ml in 0.1 N HCl and 25.45 μg/ml in phosphate buffer
(pH 7.2). The saturation solubility studies of crystallization investigation, indicating that
proliposome showing maximum solubility compared to unprocessed drug is due to the
amorphous nature of drug after film deposition method.
The saturation solubility increased with an increase in carrier proportion of all
carriers. This might be due to better wetting ability associated with soya lecithin (2 gm),
cholesterol (2 gm), sorbitol (5 gm) and TPGS (0.5 gm) of proliposomes. With stabilizer
proliposome formulation (SF2) have very fine particle size and hence large surface area, so as
the proportion of carrier increases; a large surface is presented for adsorption of the drug
crystals. Enhancement in saturation solubility was found to in order of SF2 > SF1. The
solubility of prepared proliposomes in 0.1 N HCl (pH 1.2) and phosphate buffer (pH 7.2) are
represented in Table. 12 figure. 24.









1. Pure 19.67 ± 0.04 25.45 ± 0.23
2. SF1 73.24 ± 0.48 84.31 ± 0.16
3. SF2 91.73 ± 0.17 98.21 ± 0.53
Mean of three observation ± SD.
Figure. 24: Saturation solubility studies of pure drug and proliposomes.
IN – VITRO DISSOLUTION STUDIES:
The most important feature of proliposome is the increase in the dissolution velocity,
not only because of increase in surface area but also because of increasing saturation
solubility. Silymarin is a poorly soluble drug. Its solubility is pH dependant increasing with
0.1 N HCl (pH 1.2) and phosphate buffer (pH 7.2) was selected for dissolution studies to
stimulate gastric condition and allows the greater discrimination of our processing effects. In
order to assess the goal of improving the dissolution rate of lyophilized silymarin in
proliposome was achieved. In-vitro dissolution profile of the percentage release versus time
profile of pure silymarin and different silymarin proliposome samples were determined in 0.1
N HCl and phosphate buffer under sink condition.
In-vitro drug release data from the proliposome were carried out for 12 hours and
graphically represented as percentage drug release versus time profile (Figure 25 and 26).
The dissolution rate of pure drug is very low. Only 31% of the drug was released in
0.1 N HCl and 37 % of the drug were released in phosphate buffer at the end of 12 hours. On
the contrary, proliposome dissolution rate is increased more than the pure drug. This could be
due to the increased surface area of the drug and possible better contact between the
proliposome and dissolution medium. In case of proliposome formulations SF1 and SF2
showed that 79.71% (SF1), 93.7 % (SF2) (in 0.1 N HCl) (table. 13) and 89.78% (SF1),
98.35% (SF2) (in phosphate buffer) (table. 14) drug was released at the end the end of 12
hours with increasing carrier proportion. Based on the above data SF2 shows maximum























Table. 13: Comparative dissolution profile of lyophilized proliposome and pure drug in
acid buffer (pH 1.2)
S.No Time in Hours
Percent of (±SD) drug release
PURE SF1 SF2
1. 0 0.00 ± 0.0 0.00 ± 0.00 0.00 ± 0.0
2. 1 5.43 ± 0.04 12.68 ± 0.31 16.30 ± 0.12
3. 2 13.29 ± 0.46 21.75 ± 0.37 24.78 ± 0.52
4. 3 16.93 ± 0.28 27.82 ± 0.46 32.66 ± 0.27
5. 4 21.18 ± 0.32 32.08 ± 0.32 41.50 ± 0.18
6. 5 23.01 ±0.26 40.57 ± 0.07 49.65 ± 0.01
7. 6 23.64 ± 0.17 46.05 ± 0.01 59.37 ± 0.12
8. 7 25.48 ± 0.05 53.95 ±0.14 69.10 ± 0.15
9. 8 26.72 ± 0.32 62.47 ± 0.07 80.05 ±0.05
10. 9 27.35 ± 0.21 72.20 ± 0.26 88.60 ± 0.32
11. 10 28.59 ± 0.14 77.12 ± 0.18 90.51 ± 0.08
12. 11 29.22 ± 0.42 79.62 ± 0.25 93.63 ± 0.13
13. 12 31.07 ± 0.29 79.71 ± 0.07 93.73 ± 0.03
Mean of three observation ± SD.
Table. 14: Comparative dissolution profile of lyophilized proliposome and pure drug in




Percent of (±SD) drug release
PURE SF1 SF2
1. 0 0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0
2. 1 1.56 ± 0.03 29.47 ± 0.02 35.12 ± 0.07
3. 2 5.33 ± 0.07 35.15 ± 0.08 40.49 ± 0.14
4. 3 8.78 ± 0.14 39.89 ± 0.16 47.43 ± 0.19
5. 4 12.24 ± 0.15 45.27 ± 0.23 54.70 ± 0.34
6. 5 16.02 ± 0.28 52.84 ± 0.24 62.60 ± 0.38
7. 6 17.92 ± 0.34 62.62 ± 0.33 71.45 ± 0.45
8. 7 22.64 ± 0.39 67.40 ± 0.41 77.17 ± 0.36
9. 8 27.37 ± 0.28 72.49 ± 0.35 84.47 ± 0.32
10. 9 31.16 ± 0.31 79.78 ± 0.37 89.58 ± 0.06
11. 10 34.02 ± 0.25 85.51 ± 0.16 92.50 ± 0.22
12. 11 37.51 ± 0.08 89.66 ± 0.13 98.25 ± 0.18
13. 12 37.55 ± 0.18 89.78 ± 0.07 98.35 ± 0.09
Mean of three observation ± SD.
Figure. 25: Comparative dissolution study of different silymarin formulations in acid
buffer (pH 1.2)
Figure. 26: Comparative dissolution study of different silymarin formulations in


























































The in-vitro permeability study was carried out using Franz Diffusion Cell. After 1
hour of diffusion, 50.33% (SF1) and 64.83% (SF2) of the drug was diffused from the
lyophilized proliposome respectively, while from pure drug, the diffusion was found to be
26.61%. Thus, the amount of the drug diffused through the nitro cellulose membrane has
doubled when it is given in the form of a proliposome. It can be clearly seen that the
permeation of the drug from lyophilized proliposome is much faster than the pure drug. The
enhanced diffusion may be explained in terms of the huge specific surface area of the
proliposome droplets and improved permeation of the silymarin because of the presence of
surfactant, which reduces the interfacial tension of formulation. The results are shown in
Table. 15 and Figure. 27.
Table. 15: Comparative permeability studies of lyophilized proliposome and pure drug
in phosphate buffer (pH 7.2).
S.No Time in minutes Silymarin SF1 SF2
1. 10 05.03 % 14.09 % 19.12 %
2. 20 09.06 % 21.23 % 31.33 %
3. 30 13.15 % 29.42 % 43.62 %
4 40 16.26 % 37.67 % 54.98 %
5. 50 26.43 % 50.00 % 64.40 %
6. 60 26.61 % 50.33 % 64.83 %
Figure. 27: Comparative permeability studies of lyophilized proliposomes and pure
drug in phosphate buffer (pH 7.2).
SELECTION OF BEST FORMULATIONS
From the above data of characterization studies, SF2 shows leading potential
formulation compared to SF1. Pharmacological activities were performed by using SF2.
PARAMETERS ASSESSED FOR LIVER FUNCTIONS
CIS administration resulted in significant elevation of bilirubin, triglycerides, total
cholesterol, AST, ALT and ALP and bilirubin levels and that of protein levels were
significantly decreased compared to the normal control group indicating liver damage.
Pretreatment with naringenin, silymarin and SF2 remarkably prevented the biological
changes induced by CIS. The effect of silymarin and SF2 on liver parameters was presented
in Table.16 & 17, figure. 28 & 29. Administration of silymarin and SF2 at the doses of 10







































I 1.42 ± 0.02 0.84 ± 0.01 8.25 ± 0.20 5.26 ± 0.06
II 3.28 ± 0.05 1.54 ± 0.03 4.75 ± 0.40 2.57 ± 0.33
III 2.02 ± 0.01 0.74 ± 0.01 7.23 ± 0.04 4.78 ± 0.02
IV 3.16 ± 0.01** 1.13 ± 0.02** 6.33 ± 0.06* 4.90 ± 0.09**







AST  (U/L) ALT (U/L) ALP    (U/L)
I 155±3.24 203.5±3.41 106.83± 0.98 43.35±1.88 105.66±0.55
II 232±4.39 379.66±5.02 168.5±1.2 276.15±6.05 213.0±1.36
III 167±3.92 244.0±5.01 115.±1.07 104.2±3.71 165.0±1.75
IV 205±4.96** 308.16±3.5** 137.16±1.07** 196.1±3.21 197.66±1.11**
V 180±5.04* 276±4.42** 123.5±1.05** 174.4±6.12 174.66±1.54**
Value represents as mean ± S.E.M. * *p < 0.01, significant difference compared with control group, *
p < 0.05, significant difference compared with control group (n = 6).
Figure: 28. Effect of silymarin & SF2 on liver function.


























































Silymarin proliposome was successfully prepared by film deposition method. This
method of manufacturing was found to be simple, did not require specialized equipments and
has scale – up feasibility. The proliposome was converted into dry powder by lyophilization
in order to increase its stability. From the reports, the particle size and zeta potential values
were measured immediately after preparation of proliposome. The particle size of the
lyophilized proliposome is homogenous in size and size distribution. All the formulation
showed lower particle sizes. Zeta potential is an indication of the stability of the
proliposomes. The Zeta potential of formulation was around ± 20 mV. The zeta potential of
best formulation (SF2) indicating good quality.
In FT-IR study proliposome showed the characteristic peeks due to pure silymarin
without any markable change in their position, indicating no chemical interaction between
silymarin and polymers. In-vitro dissolution studies indicated that the dissolution rate of the
drug from the lyophilized proliposomes is significantly higher than that of the pure drug. This
study indicated higher drug diffusion from proliposome, possibly due to higher increases in
saturation solubility and dissolution rate than plain drug. The in-vitro permeability results
show that the drug diffusion across the nitrocellulose membrane from proliposome is
significantly higher than the plain drug.
From the previous reports the hepatotoxicity play a critical role in pathogenesis of
CIS induced hepato toxicity. Pretreatment with SF2 significantly attenuated CIS-induced
functional liver compared to silymarin. One possible reason of SF2-mediated preservation is
that, before CIS administration, pretreatment with SF2 could permit inception of free radicals
produced by CIS prior to reaching DNA and causing damage. The study provides strong
evidence for the use of the SF2 has hepato protective activity against CIS induced damage in
liver. Therefore, SF2 could be an encouraging chemoprotective agent to approach CIS-
mediated toxicity.
These observations lead us to the conclusion that proliposome seems to be a
promising drug delivery system, which can provide an effective and practical solution to the
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